LivaNova PLC (NASDAQ:LIVN) Receives $69.17 Consensus Target Price from Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $69.17.

LIVN has been the subject of a number of recent analyst reports. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Mizuho cut their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st.

LivaNova Trading Down 1.6 %

Shares of LIVN opened at $49.71 on Tuesday. The business’s 50-day moving average price is $52.19 and its 200-day moving average price is $51.80. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a twelve month low of $43.15 and a twelve month high of $64.47. The stock has a market cap of $2.70 billion, a PE ratio of 118.36 and a beta of 0.98.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after buying an additional 44,049 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after acquiring an additional 806,374 shares during the period. Vanguard Group Inc. grew its position in LivaNova by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after acquiring an additional 62,480 shares during the last quarter. Geode Capital Management LLC increased its stake in LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after purchasing an additional 8,331 shares during the period. Finally, Victory Capital Management Inc. lifted its position in LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after purchasing an additional 133,401 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.